New stem cell approach targets functional cure for diabetes - News-Medical
Researchers are exploring a functional cure for Type 1 diabetes through immune-engineered stem cell therapies that eliminate the need for immunosuppression.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
A new stem cell approach is targeting a functional cure for Type 1 diabetes. This includes the first human trial exploring immune-engineered cell therapy and research focused on helping transplanted cells thrive within the patient.
Coverage from The Manila Times and News-Medical highlights Sana Biotechnology's role, specifically citing a publication in The New England Journal of Medicine regarding the durability of hypoimmune-modified islet cell transplantation. Other reporting from Bioengineer.org and Newswise emphasizes the goal of achieving treatment without the use of immunosuppression.
Attention is now on the European Association for the Study of Diabetes (EASD), where Sana Biotech is expected to provide a cell therapy update.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 23m ago.
Quick answers
What is the goal of the new stem cell approach?
The approach targets a functional cure for diabetes.
Which company is providing updates on its cell therapy?
Sana Biotechnology is heading to the EASD with a diabetes cell therapy update.
What was the significance of the NEJM publication?
The publication highlighted long-term data and the durability of hypoimmune-modified islet cell transplantation without the need for immunosuppression.
Coverage (5)
- First Human Trial Explores Immune-Engineered Cell Therapy for Type 1 Diabetes Bioengineer.org · 1d ago
- Sana Biotech heads to EASD with diabetes cell therapy update Longevity.Technology · 1d ago
- New Research Seeks to Help Transplanted Cells Thrive in Type 1 Diabetes Treatment Newswise · 1d ago
- Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 D The Manila Times · 1d ago
- New stem cell approach targets functional cure for diabetes News-Medical · 1d ago broke it first
People, places & organizations
Topics
Related trends
The data that led an AI biotech to pick up Novo's Parkinson's stem cell therapy
An AI biotech firm has acquired Novo's Parkinson's stem cell therapy following promising data from initial human trials.